The positive movement in Psyence Biomedical's stock price can be attributed to the Indiana legislature's decision to fund psilocybin clinical research trials. This development is seen as a significant step forward for the company, potentially opening up new opportunities in the field of psychedelic medicine. The direct involvement in psilocybin research, a key area of Psyence Biomedical's focus, is likely to be viewed positively by investors, hence the uptick in stock price.